Puma Biotechnology reports quarterly results and 2026 revenue guidance

Puma Biotechnology reported quarterly earnings results on February 26 and issued 2026 guidance that projects first-quarter total revenue of US$38 million to US$42 million and a net loss of US$8 million to US$10 million. For full year 2026, the company guided to total revenue of US$214 million to US$221 million and net income of US$10 million to US$13 million.

The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.02. Revenue was $75.50 million for the quarter, compared to the consensus estimate of $68.60 million. Puma Biotechnology had a net margin of 13.62% and a return on equity of 27.80%.

For the first quarter of 2026, Puma Biotechnology projected net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million. For full year 2026, the company guided to net product revenue of US$194 million to US$198 million and royalty revenue of US$20 million to US$23 million.

In the fourth quarter, Ritholtz Wealth Management raised its stake in shares of Puma Biotechnology by 47.4%, according to its most recent filing with the Securities and Exchange Commission. The fund owned 694,001 shares after acquiring an additional 223,234 shares during the quarter. Ritholtz Wealth Management owned approximately 1.38% of Puma Biotechnology worth $4.129 million at the end of the most recent quarter.

Other institutional investors also changed their positions. Cerity Partners LLC bought a new position during the second quarter valued at $36,000. BNP Paribas Financial Markets boosted its stake by 39.7% during the third quarter and owned 8,056 shares valued at $43,000 after acquiring an additional 2,290 shares. Wealth Enhancement Advisory Services LLC bought a new position during the fourth quarter valued at $59,000, Caprock Group LLC bought a new position during the third quarter valued at $59,000, and Perkins Capital Management Inc. bought a new position during the third quarter valued at $65,000. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology stock opened at $7.78 on Friday. The firm's 50-day moving average is $6.62 and its 200-day moving average is $5.91. Puma Biotechnology has a 1 year low of $2.68 and a 1 year high of $7.90. The company has a market cap of $395.92 million, a P/E ratio of 12.75 and a beta of 1.19.

Puma Biotechnology is a late-stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. The company's lead product is neratinib, marketed under the brand name Nerlynx in the United States, and it received FDA approval in 2017 for extended adjuvant treatment of early-stage HER2-positive breast cancer.